Clinical Trial Alert: New Vagus Nerve Stimulation Study For Depression
Clinical trial alert: Non-invasive ultrasonic auricular vagus nerve stimulation (uaVNS) is under investigation. Launched December 16, 2025, the trial employs low-intensity focused ultrasound (LIFU) via a wearable ear device. LIFU targets the auricular branch of the vagus nerve. Acoustic pressure waves mechanically activate voltage-gated ion channels. This promotes afferent signaling to brainstem nuclei, enhancing parasympathetic outflow. Inflammation is modulated via the cholinergic anti-inflammatory pathway. Compared to transcutaneous electrical VNS (taVNS), uaVNS offers superior penetration and spatial precision. No skin irritation. The double-blind, randomized, sham-controlled study includes 80 adults with major depressive disorder. Protocol: 30-min daily sessions for 12 weeks. Primary endpoint: MADRS reduction. Secondary: HRV, cytokine levels, fMRI. Preclinical rodent models show uaVNS yields a 25% greater HRV increase. Locus coeruleus norepinephrine modulation is 40% more robust than taVNS. https://clinicaltrials.gov/study/NCT07283913